195 related articles for article (PubMed ID: 23098072)
1. Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.
Huynh AS; Chung WJ; Cho HI; Moberg VE; Celis E; Morse DL; Vagner J
J Med Chem; 2012 Nov; 55(22):9751-62. PubMed ID: 23098072
[TBL] [Abstract][Full Text] [Related]
2. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components.
Dobrovolskaia MA; Medvedev AE; Thomas KE; Cuesta N; Toshchakov V; Ren T; Cody MJ; Michalek SM; Rice NR; Vogel SN
J Immunol; 2003 Jan; 170(1):508-19. PubMed ID: 12496438
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Structure-Activity Relationship of
Chen Z; Zhang L; Yang J; Zheng L; Hu F; Duan S; Nandakumar KS; Liu S; Yin H; Cheng K
J Med Chem; 2021 Jun; 64(11):7371-7389. PubMed ID: 34029463
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response.
Boyd JH; Mathur S; Wang Y; Bateman RM; Walley KR
Cardiovasc Res; 2006 Dec; 72(3):384-93. PubMed ID: 17054926
[TBL] [Abstract][Full Text] [Related]
5. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.
Zom GG; Khan S; Britten CM; Sommandas V; Camps MG; Loof NM; Budden CF; Meeuwenoord NJ; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
Cancer Immunol Res; 2014 Aug; 2(8):756-64. PubMed ID: 24950688
[TBL] [Abstract][Full Text] [Related]
6. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG; Wiesmüller KH; Chandran PA; Zelba H; Rusch E; Gouttefangeas C; Kowalewski DJ; Di Marco M; Haen SP; Walz JS; Gloria YC; Bödder J; Schertel JM; Tunger A; Müller L; Kießler M; Wehner R; Schmitz M; Jakobi M; Schneiderhan-Marra N; Klein R; Laske K; Artzner K; Backert L; Schuster H; Schwenck J; Weber ANR; Pichler BJ; Kneilling M; la Fougère C; Forchhammer S; Metzler G; Bauer J; Weide B; Schippert W; Stevanović S; Löffler MW
J Immunother Cancer; 2019 Nov; 7(1):307. PubMed ID: 31730025
[TBL] [Abstract][Full Text] [Related]
7. The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity.
Toussi DN; Liu X; Massari P
Clin Vaccine Immunol; 2012 Jul; 19(7):1093-101. PubMed ID: 22623652
[TBL] [Abstract][Full Text] [Related]
8. Porin of Shigella dysenteriae directly promotes toll-like receptor 2-mediated CD4+ T cell survival and effector function.
Biswas A; Banerjee P; Biswas T
Mol Immunol; 2009 Sep; 46(15):3076-85. PubMed ID: 19576636
[TBL] [Abstract][Full Text] [Related]
9. Differential role of Dok1 and Dok2 in TLR2-induced inflammatory signaling in glia.
Downer EJ; Johnston DG; Lynch MA
Mol Cell Neurosci; 2013 Sep; 56():148-58. PubMed ID: 23659921
[TBL] [Abstract][Full Text] [Related]
10. Toll like Receptor 2 engagement on CD4
Karim AF; Reba SM; Li Q; Boom WH; Rojas RE
Eur J Immunol; 2017 Sep; 47(9):1513-1524. PubMed ID: 28665005
[TBL] [Abstract][Full Text] [Related]
11. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor ligands directly promote activated CD4+ T cell survival.
Gelman AE; Zhang J; Choi Y; Turka LA
J Immunol; 2004 May; 172(10):6065-73. PubMed ID: 15128790
[TBL] [Abstract][Full Text] [Related]
13. Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1.
Cho S; Kim SB; Lee Y; Song EC; Kim U; Kim HY; Suh JH; Goughnour PC; Kim Y; Yoon I; Shin NY; Kim D; Kim IK; Kang CY; Jang SY; Kim MH; Kim S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461342
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 2-mediated modulation of growth and functions of regulatory T cells by oral streptococci.
Saeki A; Segawa T; Abe T; Sugiyama M; Arimoto T; Hara H; Hasebe A; Ohtani M; Tanizume N; Ohuchi M; Kataoka H; Kawanami M; Yokoyama A; Shibata K
Mol Oral Microbiol; 2013 Aug; 28(4):267-80. PubMed ID: 23413817
[TBL] [Abstract][Full Text] [Related]
15. A new cell-based innate immune receptor assay for the examination of receptor activity, ligand specificity, signalling pathways and the detection of pyrogens.
Burger-Kentischer A; Abele IS; Finkelmeier D; Wiesmüller KH; Rupp S
J Immunol Methods; 2010 Jun; 358(1-2):93-103. PubMed ID: 20385141
[TBL] [Abstract][Full Text] [Related]
16. Toll-Like Receptor 2 Ligation Enhances HIV-1 Replication in Activated CCR6+ CD4+ T Cells by Increasing Virus Entry and Establishing a More Permissive Environment to Infection.
Bolduc JF; Ouellet M; Hany L; Tremblay MJ
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928019
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.
Wang Y; Su L; Morin MD; Jones BT; Mifune Y; Shi H; Wang KW; Zhan X; Liu A; Wang J; Li X; Tang M; Ludwig S; Hildebrand S; Zhou K; Siegwart DJ; Moresco EMY; Zhang H; Boger DL; Beutler B
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8698-E8706. PubMed ID: 30150374
[TBL] [Abstract][Full Text] [Related]
18. Immune Regulation of Toll-Like Receptor 2 Engagement on CD4
Wu XZ; Zhou Q; Lin H; Zhai K; Wang XJ; Yang WB; Shi HZ
Am J Respir Cell Mol Biol; 2017 Mar; 56(3):342-352. PubMed ID: 27767332
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2).
Murgueitio MS; Ebner S; Hörtnagl P; Rakers C; Bruckner R; Henneke P; Wolber G; Santos-Sierra S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2680-2689. PubMed ID: 28734965
[TBL] [Abstract][Full Text] [Related]
20. Naive CD4
Ibrahim M; Scozzi D; Toth KA; Ponti D; Kreisel D; Menna C; De Falco E; D'Andrilli A; Rendina EA; Calogero A; Krupnick AS; Gelman AE
J Immunol; 2018 Jan; 200(2):847-856. PubMed ID: 29212908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
